Loading clinical trials...
Loading clinical trials...
Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
Conditions
Interventions
ETBX-021
Locations
2
United States
Chan Soon-Shiong Institute for Medicine
El Segundo, California, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
Start Date
March 4, 2017
Primary Completion Date
August 16, 2018
Completion Date
August 16, 2018
Last Updated
January 13, 2025
NCT06066138
NCT05372640
NCT04235764
NCT00026884
NCT05245812
NCT06305754
Lead Sponsor
NantBioScience, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions